Display options
Cite
Lo J, Papa N, Bolton DM, et al. Australian patterns of prostate cancer care: Are they evolving?. Prostate Int. 2015;4(1):20-4doi: 10.1016/j.prnil.2015.11.001.
Lo, J., Papa, N., Bolton, D. M., Murphy, D., & Lawrentschuk, N. (2016). Australian patterns of prostate cancer care: Are they evolving?. Prostate international, 4(1), 20-4. https://doi.org/10.1016/j.prnil.2015.11.001
Lo, Jonathon, et al. "Australian patterns of prostate cancer care: Are they evolving?." Prostate international vol. 4,1 (2016): 20-4. doi: https://doi.org/10.1016/j.prnil.2015.11.001
Lo J, Papa N, Bolton DM, Murphy D, Lawrentschuk N. Australian patterns of prostate cancer care: Are they evolving?. Prostate Int. 2016 Mar;4(1):20-4. doi: 10.1016/j.prnil.2015.11.001. Epub 2015 Dec 08. PMID: 27014660; PMCID: PMC4789340.
Copy Download .nbib Format: NLM
Share it on

Prostate Int. 2016 Mar;4(1):20-4. doi: 10.1016/j.prnil.2015.11.001. Epub 2015 Dec 08.

Australian patterns of prostate cancer care: Are they evolving?.

Prostate international

Jonathon Lo, Nathan Papa, Damien M Bolton, Declan Murphy, Nathan Lawrentschuk

Affiliations

  1. University of Melbourne, Department of Surgery, Austin Health, Melbourne, Australia.
  2. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  3. University of Melbourne, Department of Surgery, Austin Health, Melbourne, Australia; Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.

PMID: 27014660 PMCID: PMC4789340 DOI: 10.1016/j.prnil.2015.11.001

Abstract

BACKGROUND: Approaches to prostate cancer (PCa) care have changed in recent years out of concern for overdiagnosis and overtreatment. Despite these changes, many patients continue to undergo some form of curative treatment and with a growing perception among multidisciplinary clinicians that more aggressive treatments are being favored. This study examines patterns of PCa care in Australia, focusing on current rates of screening and aggressive interventions that consist of high-dose-rate (HDR) brachytherapy and pelvic lymph node dissection (PLND).

METHODS: Health services data were used to assess Australian men undergoing PCa screening and treatment from 2001 to 2014. Age-specific rates of prostate-specific antigen (PSA) screening were calculated. Ratios of radical prostatectomy (RP) with PLND to RP without PLND, and HDR brachytherapy to low-dose-rate (LDR) brachytherapy were determined by state jurisdictions.

RESULTS: From 2008, the rate of PSA screening trended downward significantly with year for all age ranges (P < 0.02) except men aged ≥ 85 (P = 0.56). PLND rates for 2008-2014 were lower than rates for 2001-2007 across all states and territories. From 2008 to 2014, PLND was performed ≥ 2.7 times more frequently in New South Wales and the Australian Capital Territory than in other jurisdictions. Since 2007, brachytherapy practice across Australia has evolved towards a relatively low use of HDR brachytherapy (ratio of HDR to LDR brachytherapy < 0.5 for all jurisdictions except the Australian Capital Territory).

CONCLUSION: Rates of PLND and HDR brachytherapy for PCa have declined in Australia, providing evidence for the effect of stage migration due to widespread PSA screening. Currently, PSA screening rates remain high among older men, which may expose them to unnecessary investigations and treatment-related morbidity.

Keywords: Brachytherapy; Lymph node excision; Mass screening; Prostatectomy; Prostatic neoplasms

References

  1. Med J Aust. 2012 Apr 2;196(6):395-8 - PubMed
  2. Aust N Z J Public Health. 2014 Oct;38(5):449-54 - PubMed
  3. BMJ. 2009 Nov 27;339:b4817 - PubMed
  4. Radiother Oncol. 2005 Feb;74(2):137-48 - PubMed
  5. N Engl J Med. 2012 Mar 15;366(11):981-90 - PubMed
  6. J Urol. 2006 Oct;176(4 Pt 1):1382-6 - PubMed
  7. N Engl J Med. 2009 Mar 26;360(13):1310-9 - PubMed
  8. BJU Int. 2006 May;97(5):975-80 - PubMed
  9. BMC Health Serv Res. 2011 Oct 06;11:253 - PubMed
  10. J Urol. 2013 Aug;190(2):419-26 - PubMed
  11. Am J Clin Oncol. 2013 Apr;36(2):121-5 - PubMed
  12. Med J Aust. 2011 Mar 21;194(6):293-6 - PubMed
  13. BJU Int. 2015 Apr;115 Suppl 5:50-6 - PubMed
  14. BJU Int. 2011 Oct;108(8 Pt 2):E190-5 - PubMed
  15. Aust N Z J Public Health. 2013 Oct;37(5):492-4 - PubMed
  16. Eur Urol. 2014 Feb;65(2):316-24 - PubMed
  17. BJU Int. 2014 Jan;113(1):77-83 - PubMed
  18. N Engl J Med. 2012 Jul 19;367(3):203-13 - PubMed
  19. Med J Aust. 2008 Sep 15;189(6):315-8 - PubMed
  20. Urology. 2011 Feb;77(2):402-6 - PubMed
  21. Brachytherapy. 2012 Jan-Feb;11(1):20-32 - PubMed
  22. Prostate Int. 2014 Sep;2(3):127-32 - PubMed
  23. J Urol. 2003 Nov;170(5):1798-803 - PubMed
  24. Med J Aust. 2013 Jun 3;198(10):540-5 - PubMed
  25. Urology. 2006 Jul;68(1):121-5 - PubMed
  26. J Med Imaging Radiat Oncol. 2014 Feb;58(1):101-8 - PubMed
  27. Prostate Int. 2015 Sep;3(3):75-9 - PubMed
  28. Eur Urol. 2014 Jan;65(1):124-37 - PubMed
  29. BJU Int. 2014 Nov;114 Suppl 1:50-4 - PubMed
  30. BJU Int. 2012 Apr;109 Suppl 3:48-51 - PubMed
  31. BJU Int. 2010 Aug;106(4):462-9 - PubMed

Publication Types